Brain-Sensing CAR T Cells Target Pediatric Glioma
November 10, 2026
Engineered T cells use molecular switches to selectively attack brain tumors, demonstrating promising antitumor activity for diffuse midline glioma
2 min read
False
November 10, 2026
Engineered T cells use molecular switches to selectively attack brain tumors, demonstrating promising antitumor activity for diffuse midline glioma
2 min read
November 9, 2026
Researchers establish a clinical-scale, nonviral manufacturing process that directly repairs the disease-causing HBB mutation in autologous stem cells
2 min read
By Kevin J. Land
November 5, 2026
By choosing where to participate and working with specialist partners, community hospitals can bring more of the CAR T patient journey closer to home
6 min read
November 4, 2026
Higher proportions of less-differentiated T cells were associated with longer progression-free survival in a 783-patient lymphoma analysis
1 min read
November 3, 2026
The company also reported early efficacy and safety data from the Phase I Breakfree-2 study
2 min read
November 2, 2026
Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited
2 min read
By Mouj Hijazi
October 30, 2026
Erik Vaessen on the costs, complexities, and technologies shaping advanced therapy manufacturing.
5 min read
October 28, 2026
Engineered T cells resisted tacrolimus but remained sensitive to cyclosporin, providing a potential way to select or suppress them after administration
2 min read
October 28, 2026
USC researchers develop a scalable cell engineering platform that could overcome key manufacturing and therapeutic limitations of CAR-based immunotherapies
2 min read
October 26, 2026
Review calls for senescence screening and EV proteomic profiling to assess whether cell therapy products can maintain protein homeostasis after transplantation
2 min read
False
False
False
Affiliations:
Specialties:
Areas of Expertise: